

# Post-Traumatic Stress Disorder (PTSD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/P0FA96B13B45EN.html>

Date: March 2022

Pages: 265

Price: US\$ 2,000.00 (Single User License)

ID: P0FA96B13B45EN

## Abstracts

Post-Traumatic Stress Disorder (PTSD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape.

Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder (PTSD) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 10, 13, 47, 13 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Post-Traumatic Stress Disorder (PTSD) - Overview

Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development

Post-Traumatic Stress Disorder (PTSD) - Drug Profiles

Post-Traumatic Stress Disorder (PTSD) - Dormant Projects

Post-Traumatic Stress Disorder (PTSD) - Discontinued Products

Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones

Featured News & Press Releases

Mar 08, 2022: Apex Labs granted phase 2a clinical trial application approval by Health Canada for treatment of PTSD in veterans

Feb 28, 2022: Creso Pharma's wholly-owned psychedelics subsidiary, Halucenex Life Sciences secures Clinical Trial Authorisation for its phase II clinical trial with Health Canada

Feb 03, 2022: Lactocore Group findings show promise in treating anxiety and depression

Jan 25, 2022: Creso Pharma's wholly-owned psychedelics subsidiary, Halucenex Life Sciences lodges clinical trial authorisation for phase II clinical trial with Health Canada

Jan 24, 2022: Mydecine Partners with Combat Stress to treat post-traumatic stress disorder in veterans

Jan 19, 2022: Numinus announces key milestones in MAPS-sponsored MDMA-assisted therapy for PTSD clinical trial

Jan 19, 2022: Neurovation Labs announces issuance of U.S. patent covering composition and methods for detecting PTSD in living subjects

Jan 10, 2022: Mydecine achieves innovative supercomputing artificial intelligence

modeling in psychedelic drug development enabling quick screening of billions of compounds

Dec 30, 2021: Jazz Pharmaceuticals announces first patient enrolled in Phase 2 clinical trial evaluating JZP150 for once-daily treatment of adults with post-traumatic stress disorder

Nov 16, 2021: BetterLife Obtains TD-0148A behavioural pharmacology data confirming its projected non-hallucinogenic property

Nov 09, 2021: Tonix Pharmaceuticals presents Phase 1 formulation development data for TNX-601 CR in a poster presentation at CNS Summit 2021

Nov 08, 2021: Halucenex receives positive USP 61 and USP 62 results

Nov 03, 2021: COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder

Sep 27, 2021: BetterLife files patent for TD-0148A for treatment of cluster headaches and related disorders

Sep 23, 2021: Wake Network receives certificate of drug registration for microdose formulation in Jamaica

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Companies, 2022 (Contd..2)

Number of Products under Development by Companies, 2022 (Contd..3)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Ache Laboratorios Farmaceuticos SA, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Actinogen Medical Ltd, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Aision Biotechnologies Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Algernon Pharmaceuticals Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Allied Corp, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Alto Neuroscience Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Alzamend Neuro Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Anagin Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Ananda Scientific Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Apex Labs Ltd, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Aptinyx Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by ARMGO Pharma Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Artelo Biosciences Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Avicanna Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Better Life Pharmaceuticals Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionomics Ltd, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionorica SE, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by BioXcel Therapeutics Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Boehringer Ingelheim International GmbH, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Braxia Scientific Corp, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bright Minds Biosciences Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Cannabis Science Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Compass Pathways Plc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Delix Therapeutics Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Co, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by EmpathBio, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Endosane Pharmaceuticals GmbH, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Enveric Biosciences Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by EpiVario Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Evecxia Therapeutics Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Exxel Pharma Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by H. Lundbeck AS, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Halucenex Life Sciences Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Immodulon Therapeutics Ltd, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by INVENT Pharmaceuticals Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by iX Biopharma Ltd, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Jazz Pharmaceuticals Plc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Johnson & Johnson, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Kdac Therapeutics Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Lactocore Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Lennham Pharmaceuticals Inc,



2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Lixte Biotechnology Holdings Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Mindstate Design Labs, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Mydecine Innovations Group Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Nanomerics Ltd, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neuritek Therapeutics Ltd, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroPharm Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neurovation Labs Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by NRX Pharmaceuticals Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by One World Cannabis Ltd, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Pharmaceutical Co Ltd, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by PharmaTher Holdings Ltd, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Praxis Precision Medicines Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Protagenic Therapeutics Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Psy Therapeutics Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by PsyBio Therapeutics Corp, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Sage Therapeutics Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Sanofi, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Scientus Pharma Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Seelos Therapeutics, Inc., 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Synendos Therapeutics AG, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Virpax Pharmaceuticals Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by VistaGen Therapeutics Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Wake Network Inc, 2022

Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, 2022

Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, 2022 (Contd..1)

Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

## I would like to order

Product name: Post-Traumatic Stress Disorder (PTSD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/P0FA96B13B45EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P0FA96B13B45EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

